Grit Bio secures funding for development of TIL therapies

By The Science Advisory Board staff writers

July 16, 2021 -- Grit Bio has secured a round of financing that it plans to use to develop tumor-infiltrating lymphocyte (TIL) therapies. The funding amount was not disclosed.

The series A+ financing round was led by GL Ventures of Hillhouse Group, with participation by Apricot Capital and Junshi Biosciences.

Founded in 2019, Grit Bio plans to bring the first TIL therapy for solid tumors to patients in China. Its leading candidate, GT101, is being tested in clinical trials.

The company is using three technology platforms to develop the therapy: its Stable Virus Producing Cell Line (StaViral) for T-cell editing; its Immunueregulatory Target Finder (ImmuT Finder) for identifying T-cell optimization targets; and its Stemness TIL Expansion Technology (StemTexp) for making TIL into an effective cell therapy product, it said.


Copyright © 2021 scienceboard.net
 
To access all The ScienceBoard content create a free account now:


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.


Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Already have an account? Sign in here